| scholarly article | Q13442814 |
| P50 | author | Baha Sibai | Q100559638 |
| P2093 | author name string | Wei Wang | |
| Yang Xia | |||
| Chen Liu | |||
| Rodney E Kellems | |||
| Jianping Jin | |||
| Nicholas Parchim | |||
| Roxanna A Irani | |||
| Sean C Blackwell | |||
| P2860 | cites work | Serotonylation of vascular proteins important to contraction | Q21562428 |
| Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase | Q24548047 | ||
| Soluble endoglin contributes to the pathogenesis of preeclampsia | Q28244053 | ||
| Protein transamidation by transglutaminase 2 in cells: a disputed Ca2+-dependent action of a multifunctional protein | Q28247511 | ||
| Involvement of tissue transglutaminase in endothelin 1-induced hypertrophy in cultured neonatal rat cardiomyocytes | Q28576560 | ||
| Gh: a GTP-binding protein with transglutaminase activity and receptor signaling function | Q28578829 | ||
| Factor XIIIA transglutaminase crosslinks AT1 receptor dimers of monocytes at the onset of atherosclerosis | Q28589061 | ||
| Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia | Q29615916 | ||
| Dopamine 5 receptor mediates Ang II type 1 receptor degradation via a ubiquitin-proteasome pathway in mice and human cells. | Q30441613 | ||
| Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor | Q33848380 | ||
| Pathogenesis and genetics of pre-eclampsia | Q33934445 | ||
| Latest advances in understanding preeclampsia | Q34425288 | ||
| Transglutaminases: crosslinking enzymes with pleiotropic functions | Q35058528 | ||
| Transglutaminase 2: a molecular Swiss army knife | Q35693361 | ||
| Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice | Q35701236 | ||
| Transglutaminase 2 inhibitors and their therapeutic role in disease states | Q35989247 | ||
| Recent progress toward the understanding of the pathophysiology of hypertension during preeclampsia | Q37079628 | ||
| Inflammatory cytokines in the pathophysiology of hypertension during preeclampsia | Q37119326 | ||
| Cellular localization of AT1 receptor mRNA and protein in normal placenta and its reduced expression in intrauterine growth restriction. Angiotensin II stimulates the release of vasorelaxants | Q37377636 | ||
| Transglutaminase-mediated intramolecular cross-linking of membrane-bound alpha-synuclein promotes amyloid formation in Lewy bodies. | Q37447970 | ||
| The role of hypoxia and hypoxia-inducible factor-1alpha in preeclampsia pathogenesis | Q38049205 | ||
| Differential signaling by the thromboxane receptor isoforms via the novel GTP-binding protein, Gh. | Q38325669 | ||
| TNF-alpha modulates expression of the tissue transglutaminase gene in liver cells | Q38339721 | ||
| Increased tissue transglutaminase expression in human atherosclerotic coronary arteries | Q39928833 | ||
| Tissue transglutaminase expression and activity in placenta. | Q40341880 | ||
| Oxytocin receptor couples to the 80 kDa Gh alpha family protein in human myometrium. | Q42160198 | ||
| Modulation of the in situ activity of tissue transglutaminase by calcium and GTP. | Q42449902 | ||
| ATP-dependent steps in the binding of ubiquitin conjugates to the 26S proteasome that commit to degradation | Q42600957 | ||
| Changes in the metabolic footprint of placental explant-conditioned culture medium identifies metabolic disturbances related to hypoxia and pre-eclampsia. | Q43272404 | ||
| Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine | Q43873037 | ||
| Therapeutic effects of cystamine in a murine model of Huntington's disease. | Q44185981 | ||
| Tissue transglutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson's disease | Q44786885 | ||
| Antibodies from preeclamptic patients stimulate increased intracellular Ca2+ mobilization through angiotensin receptor activation | Q45069619 | ||
| Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation | Q45077697 | ||
| Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of interleukin 6. | Q51139503 | ||
| Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of tumor necrosis factor-alpha. | Q51359651 | ||
| Developmental regulation of tissue transglutaminase during human placentation and expression in neoplastic trophoblast. | Q52197515 | ||
| A role for tissue transglutaminase in stabilization of membrane-cytoskeletal particles shed from the human placenta. | Q53541406 | ||
| Prevalence of agonistic autoantibodies against the angiotensin II type 1 receptor and soluble fms-like tyrosine kinase 1 in a gestational age-matched case study. | Q54782424 | ||
| Differential expression of angiotensin II type 1 and type 2 receptors at the maternal–fetal interface: potential roles in early placental development | Q61866802 | ||
| The binding of divalent metal ions to platelet factor XIII modulates its proteolysis by trypsin and thrombin. | Q64917428 | ||
| Expression induced by interleukin-6 of tissue-type transglutaminase in human hepatoblastoma HepG2 cells | Q72214769 | ||
| AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor | Q73815485 | ||
| Effect of cystamine on blood pressure and vascular characteristics in spontaneously hypertensive rats | Q84583188 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pre-eclampsia | Q61335 |
| pathogenesis | Q372016 | ||
| protein ubiquitination | Q3547638 | ||
| P304 | page(s) | 353-361 | |
| P577 | publication date | 2013-11-04 | |
| P1433 | published in | Hypertension | Q5958695 |
| P1476 | title | Tissue transglutaminase contributes to the pathogenesis of preeclampsia and stabilizes placental angiotensin receptor type 1 by ubiquitination-preventing isopeptide modification | |
| P478 | volume | 63 |
| Q89006965 | Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology |
| Q107324240 | Autoantibodies against ACE2 and angiotensin type-1 receptors increase severity of COVID-19 |
| Q36339273 | Blockade of CD40 ligand for intercellular communication reduces hypertension, placental oxidative stress, and AT1-AA in response to adoptive transfer of CD4+ T lymphocytes from RUPP rats |
| Q34473794 | Cystamine preparations exhibit anticoagulant activity |
| Q36836373 | Elevated Transglutaminase Activity Triggers Angiotensin Receptor Activating Autoantibody Production and Pathophysiology of Preeclampsia |
| Q39198610 | Inflammation, Autoimmunity, and Hypertension: The Essential Role of Tissue Transglutaminase |
| Q36599656 | Involvement of transglutaminase 2 and voltage-gated potassium channels in cystamine vasodilatation in rat mesenteric small arteries. |
| Q36584747 | Preeclampsia and Pregnancy-Related Hypertensive Disorders |
| Q39166559 | Protein Phosphotyrosine Phosphatase 1B (PTP1B) in Calpain-dependent Feedback Regulation of Vascular Endothelial Growth Factor Receptor (VEGFR2) in Endothelial Cells: IMPLICATIONS IN VEGF-DEPENDENT ANGIOGENESIS AND DIABETIC WOUND HEALING. |
| Q55259961 | Switching-Off Adora2b in Vascular Smooth Muscle Cells Halts the Development of Pulmonary Hypertension. |
| Q46308477 | The relationship between circulating tissue transglutaminase, soluble fms-like tyrosine kinase-1, soluble endoglin and vascular endothelial growth factor in pre-eclampsia |
| Q64233038 | Tissue Transglutaminase-Mediated AT1 Receptor Sensitization Underlies Pro-inflammatory Cytokine LIGHT-Induced Hypertension |
| Q41521275 | Transglutaminase 2 in human diseases |
| Q37240779 | Transglutaminase is a Critical Link Between Inflammation and Hypertension |
Search more.